- Home
- TRML
TRML
Tourmaline Bio Inc.
as 11-07-2024 4:00pm EST
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 419.1M | IPO Year: | N/A |
| Target Price: | $64.67 | AVG Volume (30 days): | 202.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.12 - $48.31 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tourmaline Bio Inc. (TRML)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | TRML | CEO | Aug 21 '24 | Buy | $14.85 | 1,779 | $26,418.15 | 7,000 | |
| Kulkarni Sandeep Chidambar | TRML | CEO | Aug 16 '24 | Buy | $13.79 | 5,221 | $71,997.59 | 7,000 |
Latest Tourmaline Bio Inc. News
TRML Breaking Stock News: Dive into TRML Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
8 days ago
Tourmaline Bio to Present at Upcoming Investor Conferences
GlobeNewswire
24 days ago
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
GlobeNewswire
a month ago
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
GlobeNewswire
a month ago
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
GlobeNewswire
2 months ago
Tourmaline Bio to Present at Upcoming Investor Conferences
Simply Wall St.
3 months ago
Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock
GlobeNewswire
3 months ago
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Compare TRML vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRML Tourmaline Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.